AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30888330 — intervention group
Group type: EXPERIMENTAL
Intervention: tablet only
Number of subjects: 1500
Study 30888330 — intervention group
Group type: COMPARATOR
Intervention: no intervention (control)
Number of subjects: 1500
Study 28718233 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of 0.5% hyperbaric bupivacaine (Group A)
Number of subjects: 200
Study 28718233 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of 0.5% hyperbaric bupivacaine (Group B)
Number of subjects: 200
Study 26033080 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation Group (PNFG)
Number of subjects: 63
Study 26033080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates Group (PG)
Number of subjects: 63
Study 26033080 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 63
Study 23561946 — intervention group
Group type: COMPARATOR
Intervention: Doxepin (10 mg daily)
Number of subjects: 18
Study 23561946 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy with bright light therapy
Number of subjects: 18
Study 23561946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21479287 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental 95% zirconia 5% alumina ceramic
Number of subjects: 30
Study 21479287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard machined zirconia
Number of subjects: 30
Study 21479287 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft machined zirconia
Number of subjects: 30
Study 21479287 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 30
Study 19549691 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg bid the day before and the day of the procedure plus saline i.v. 0.9% 1 ml/kg/h 12-24 h before and 24 h after the procedure)
Number of subjects: 200
Study 19549691 — intervention group
Group type: COMPARATOR
Intervention: Placebo and saline at the same time intervals
Number of subjects: 200
Study 19549691 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 200
Study 16700815 — intervention group
Group type: EXPERIMENTAL
Intervention: New insoluble-matrix retropalpebral ophthalmic insert containing 5.38 mg phenylephrine and 0.28 mg tropicamide
Number of subjects: 18
Study 16700815 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 10% and tropicamide 0.5% eyedrops
Number of subjects: 18
Study 16700815 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (insert and eye drops)
Number of subjects: 18
Study 16700815 — intervention group
Group type: EXPERIMENTAL
Intervention: New insoluble-matrix retropalpebral ophthalmic insert
Number of subjects: 18
Study 14668607 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (0, 5, 10, and 15 cm H2O) in both supine and prone positions
Number of subjects: 25
Study 14668607 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 25
Study 14668607 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP and prone position together
Number of subjects: 25
Study 14668607 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP in patients with diffuse infiltrates
Number of subjects: 25
Study 14668607 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP in patients with localized infiltrates
Number of subjects: 25
Study 14668607 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower inflection point
Number of subjects: 25
Study 10960643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 200 microg
Number of subjects: 200
Study 10960643 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone 0.5 mg every 6 hours (maximum four doses)
Number of subjects: 200
Study 8985996 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution A (Methenamine)
Number of subjects: 16
Study 8985996 — intervention group
Group type: COMPARATOR
Intervention: Solution B (blank solution)
Number of subjects: 16
Study 1462902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (100 mg intravenous bolus followed by 300 mg intramuscular injection)
Number of subjects: 204
Study 1462902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 3913425 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nicergoline (Sermion) daily for 180 days
Number of subjects: 28
Study 3913425 — intervention group
Group type: COMPARATOR
Intervention: 6 mg dihydroergotamine mesilate (DHETM) daily for 180 days
Number of subjects: 28
Study 30838731 — intervention group
Group type: EXPERIMENTAL
Intervention: Green LED phototherapy
Number of subjects: 34
Study 30838731 — intervention group
Group type: COMPARATOR
Intervention: Blue LED phototherapy
Number of subjects: 34
Study 28973389 — intervention group
Group type: EXPERIMENTAL
Intervention: REALM‐R test
Number of subjects: 500
Study 28378852 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 10
Study 28378852 — intervention group
Group type: EXPERIMENTAL
Intervention: Monk fruit
Number of subjects: 10
Study 28378852 — intervention group
Group type: EXPERIMENTAL
Intervention: Stevia
Number of subjects: 10
Study 28378852 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 10
Study 24923987 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0
Study 24923987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23435091 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 375
Study 21272875 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-balloon endoscopy (SBE)
Number of subjects: 38
Study 21272875 — intervention group
Group type: COMPARATOR
Intervention: Double-balloon endoscopy (DBE)
Number of subjects: 38
Study 19709504 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (n = 10)
Number of subjects: 20
Study 19709504 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (n = 10)
Number of subjects: 20
Study 19709504 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (active rTMS and sham)
Number of subjects: 20
Study 16766000 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic human face with associated human vocalizations
Number of subjects: 0
Study 16766000 — intervention group
Group type: COMPARATOR
Intervention: Dynamic monkey face with species-appropriate vocalization
Number of subjects: 0
Study 16766000 — intervention group
Group type: COMPARATOR
Intervention: House with opening front door and creaking door sound
Number of subjects: 0
Study 16766000 — intervention group
Group type: EXPERIMENTAL
Intervention: Human face paired with non-human sound
Number of subjects: 0
Study 16766000 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual ERPs at trial onset
Number of subjects: 0
Study 15541179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuddling (nonpharmacological intervention)
Number of subjects: 95
Study 15541179 — intervention group
Group type: COMPARATOR
Intervention: Pain ratings (0-10 scale and 0-6 Faces Pain Scale)
Number of subjects: 95
Study 15541179 — intervention group
Group type: COMPARATOR
Intervention: Distress ratings (0-10)
Number of subjects: 95
Study 15541179 — intervention group
Group type: COMPARATOR
Intervention: Time to calm without intervention (seconds)
Number of subjects: 95
Study 12774159 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium infusion (1 mmol/kg)
Number of subjects: 131
Study 12774159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 9512843 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic epidural blood patch (PEBP) recommended by 37% of centres; more common in US than Canadian centres.
Number of subjects: 137250
Study 9512843 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EBP) offered most commonly at or within 24 hours of diagnosis of post-dural puncture headache (PDPH).
Number of subjects: 137250
Study 9512843 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted mobilisation advocated by 86% of centres following delivery.
Number of subjects: 137250
Study 9512843 — intervention group
Group type: EXPERIMENTAL
Intervention: Resiting the catheter at another level was the most common initial response to dural puncture.
Number of subjects: 137250
Study 8031017 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens Lithostar Plus
Number of subjects: 0
Study 8031017 — intervention group
Group type: EXPERIMENTAL
Intervention: Storz Medical Modulith SL 10
Number of subjects: 0
Study 8031017 — intervention group
Group type: COMPARATOR
Intervention: Both apparatuses
Number of subjects: 0
Study 2722372 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented water supply through handpumps and health education
Number of subjects: 623
Study 2722372 — intervention group
Group type: COMPARATOR
Intervention: No project inputs (Control)
Number of subjects: 623
Study 30745343 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual learning aid (Calibrated Periodontal Training Video)
Number of subjects: 22
Study 30745343 — intervention group
Group type: COMPARATOR
Intervention: Control group (only probing technique instruction from prior lectures)
Number of subjects: 22
Study 28241357 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (n=344)
Number of subjects: 705
Study 28241357 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=361)
Number of subjects: 705
Study 25083727 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-sprint training in hypoxia (RSH, 3000 m; FiO2, 13.8%)
Number of subjects: 17
Study 25083727 — intervention group
Group type: COMPARATOR
Intervention: Repeated-sprint training in normoxia (RSN, 300 m; FiO2, 20.9%)
Number of subjects: 17
Study 23998910 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone intake (highest quartile Q4: 1.6‐78.8 mg/d)
Number of subjects: 259
Study 23998910 — intervention group
Group type: COMPARATOR
Intervention: Isoflavone intake (Q4)
Number of subjects: 259
Study 23998910 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone intake
Number of subjects: 259
Study 22133962 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthwash (experimental group)
Number of subjects: 33
Study 22133962 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash (control group)
Number of subjects: 33
Study 19734392 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention
Number of subjects: 506
Study 19734392 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 506
Study 19734392 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-diagnosed depressed women
Number of subjects: 506
Study 19734392 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed women
Number of subjects: 506
Study 16269419 — intervention group
Group type: EXPERIMENTAL
Intervention: LBBB
Number of subjects: 17073
Study 16269419 — intervention group
Group type: EXPERIMENTAL
Intervention: RBBB with anterior AMI
Number of subjects: 17073
Study 16269419 — intervention group
Group type: EXPERIMENTAL
Intervention: RBBB with inferior AMI
Number of subjects: 17073
Study 16269419 — intervention group
Group type: EXPERIMENTAL
Intervention: New LBBB
Number of subjects: 17073
Study 16269419 — intervention group
Group type: EXPERIMENTAL
Intervention: New RBBB with anterior AMI
Number of subjects: 17073
Study 16269419 — intervention group
Group type: EXPERIMENTAL
Intervention: New RBBB with inferior AMI
Number of subjects: 17073
Study 15281334 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-based intervention to link low-income urban children with asthma to their primary care providers
Number of subjects: 527
Study 11038995 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuan Fei Ding Chuan Wan and Xiao Chuan Gu Ben Wan
Number of subjects: 600
Study 11038995 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 600
Study 9052630 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial clinical presentation features
Number of subjects: 420
Study 9052630 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal infiltrate, cataract wound abnormalities, afferent pupillary defect, loss of red reflex, initial light perception‐only vision, symptom onset within 2 days of surgery
Number of subjects: 420
Study 9052630 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualized retinal vessel
Number of subjects: 420
Study 9052630 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 420
Study 9052630 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye pain
Number of subjects: 420
Study 8159835 — intervention group
Group type: EXPERIMENTAL
Intervention: sulbactam/ampicillin 1 g IV before surgical incision and then 8-hourly x 3 days
Number of subjects: 200
Study 8159835 — intervention group
Group type: COMPARATOR
Intervention: cefuroxime 2 g IV before surgical incision and then 8-hourly x 3 days
Number of subjects: 200
Study 6461677 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 33
Study 6461677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 30376079 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumicitabine (ALS‐008176 or JNJ‐64041575)
Number of subjects: 0
Study 28729019 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV/dPly/PhtD-10
Number of subjects: 575
Study 28729019 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV/dPly/PhtD-30
Number of subjects: 575
Study 28729019 — intervention group
Group type: COMPARATOR
Intervention: PHiD-CV
Number of subjects: 575
Study 28729019 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 575
Study 26263244 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs
Number of subjects: 0
Study 26263244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23823005 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC insertion
Number of subjects: 49
Study 22913642 — intervention group
Group type: EXPERIMENTAL
Intervention: Educative intervention involving peer-visit from a trained GP to motivate patient-centred communication techniques and decision aids.
Number of subjects: 780
Study 22913642 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group).
Number of subjects: 780
Study 22913642 — intervention group
Group type: EXPERIMENTAL
Intervention: Educative intervention (I).
Number of subjects: 780
Study 19896624 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent training
Number of subjects: 36
Study 19896624 — intervention group
Group type: COMPARATOR
Intervention: Proctored training
Number of subjects: 36
Study 17922355 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructive case-based exams
Number of subjects: 382
Study 17922355 — intervention group
Group type: EXPERIMENTAL
Intervention: Case discussions and question-answer sessions
Number of subjects: 382
Study 17198589 — intervention group
Group type: EXPERIMENTAL
Intervention: FES group (n = 13), receiving standard rehabilitation combined with FES 30 minutes per day, 5 days per week for 3 weeks.
Number of subjects: 46
Study 17198589 — intervention group
Group type: EXPERIMENTAL
Intervention: FES group (n = 13)
Number of subjects: 46
Study 17198589 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 15)
Number of subjects: 46
Study 17198589 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 13)
Number of subjects: 46
Study 12595509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AGE diet for 4 weeks
Number of subjects: 26
Study 12595509 — intervention group
Group type: COMPARATOR
Intervention: High AGE diet for 4 weeks
Number of subjects: 26
Study 10528958 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Information System (HIS) implemented in 24 district hospitals (early implementation)
Number of subjects: 42
Study 10528958 — intervention group
Group type: COMPARATOR
Intervention: Hospital Information System (HIS) not implemented in 24 district hospitals (late implementation)
Number of subjects: 42
Study 7497556 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional surgical tracheostomy
Number of subjects: 53
Study 7497556 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous dilational tracheostomy
Number of subjects: 53
Study 1683196 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium supplementation (600 micrograms daily divided into three doses)
Number of subjects: 72
Study 1683196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical appearance and taste)
Number of subjects: 72
Study 1683196 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium supplementation
Number of subjects: 72
Study 6749826 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline-perphenazine (100/8-150/12 mg/day)
Number of subjects: 130
Study 6749826 — intervention group
Group type: COMPARATOR
Intervention: Doxepin (100-150 mg/day)
Number of subjects: 130
Study 30642441 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every 3 weeks)
Number of subjects: 425
Study 30642441 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 425
Study 30642441 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 425
Study 30642441 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 425
Study 29075343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 mL over seven days followed by 10 mL until day 30)
Number of subjects: 100
Study 29075343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25359354 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate isoniazid treatment
Number of subjects: 60
Study 25359354 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred isoniazid treatment
Number of subjects: 60
Study 23075453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP) at a standardised pressure of 30 N
Number of subjects: 50
Study 23075453 — intervention group
Group type: COMPARATOR
Intervention: No cricoid pressure (CP)
Number of subjects: 50
Study 21742465 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 2344
Study 21742465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2344
Study 18777410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 80
Study 18777410 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 80
Study 18777410 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 80
Study 18777410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and Exemestane
Number of subjects: 80
Study 17072689 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol/remifentanil/rocuronium (TIVA)
Number of subjects: 50
Study 17072689 — intervention group
Group type: COMPARATOR
Intervention: Inhalational opioid‐free anesthesia with sevoflurane/rocuronium (GAS)
Number of subjects: 50
Study 12934722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (safety audit and safety behavior training)
Number of subjects: 990
Study 12934722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 990
Study 10618560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (goal dose 100 microgram/min)
Number of subjects: 100
Study 10618560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 100
Study 8939149 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg zileuton
Number of subjects: 373
Study 8939149 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg zileuton
Number of subjects: 373
Study 8939149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 1393176 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed multisensory stimulation (SDS)
Number of subjects: 6
Study 1393176 — intervention group
Group type: COMPARATOR
Intervention: Non-directed stimulation (NDS)
Number of subjects: 6
Study 3919401 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 0
Study 3919401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29878939 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized fluid therapy using noninvasive cardiac output (Clearsight system) monitor
Number of subjects: 40
Study 29878939 — intervention group
Group type: COMPARATOR
Intervention: Protocolized fluid therapy approach
Number of subjects: 40
Study 29246348 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐item preconception health screening and counseling and 90‐day multivitamin supply
Number of subjects: 415
Study 29246348 — intervention group
Group type: COMPARATOR
Intervention: Preconception health and community resource handouts and 90‐day multivitamin supply
Number of subjects: 415
Study 27052531 — intervention group
Group type: COMPARATOR
Intervention: Creatine 3 g/d
Number of subjects: 605
Study 27052531 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine plus Folic Acid 400 μg/d
Number of subjects: 605
Study 24314907 — intervention group
Group type: COMPARATOR
Intervention: Schizophrenia patients (SZ)
Number of subjects: 73
Study 24314907 — intervention group
Group type: COMPARATOR
Intervention: Bipolar disorder type I patients (BP)
Number of subjects: 73
Study 24314907 — intervention group
Group type: EXPERIMENTAL
Intervention: Small SZ subgroup not receiving antipsychotic medication (n=10)
Number of subjects: 73
Study 22425936 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (TTM tailored interventions)
Number of subjects: 9461
Study 22425936 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9461
Study 20061906 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg monthly intramuscular octreotide
Number of subjects: 21
Study 20061906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17283005 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg position with hip flexion (hip flexion group)
Number of subjects: 40
Study 17283005 — intervention group
Group type: COMPARATOR
Intervention: Trendelenburg position without hip flexion (control group)
Number of subjects: 40
Study 16109001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral school-based universal primary prevention program
Number of subjects: 347
Study 16109001 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 347
Study 11535320 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine administered by needle-free jet injector (JI)
Number of subjects: 304